Christine Johnston1,2,3, Elizabeth R Brown4,3,5, Jenell Stewart1,6, Helen C Stankiewicz Karita1, Patricia J Kissinger7, John Dwyer8, Sybil Hosek9,10, Temitope Oyedele9,10, Michael K Paasche-Orlow11,12, Kristopher Paolino13, Kate B Heller6, Hannah Leingang6, Harald S Haugen6, Tracy Q Dong3, Anna Bershteyn14, Arun R Sridhar15, Jeanne Poole15, Peter A Noseworthy16, Michael J Ackerman16, Susan Morrison6, Alexander L Greninger2,3, Meei-Li Huang3, Keith R Jerome2,3, Mark H Wener2,17, Anna Wald1,2,18,3, Joshua T Schiffer1,3, Connie Celum1,18,6, Helen Y Chu1,18,6, Ruanne V Barnabas1,2,18,3, Jared M Baeten1,18,6. 1. Division of Allergy and Infectious Diseases, University of Washington, United States. 2. Department of Laboratory Medicine and Pathology, University of Washington, United States. 3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Department of Biostatistics, University of Washington, United States. 5. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 6. Department of Global Health, University of Washington, United States. 7. School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States. 8. School of Medicine, Tulane University, New Orleans, LA, United States. 9. John H. Stroger, Jr., Hospital of Cook County, Chicago, IL, United States. 10. Rush University Medical Center, Chicago, IL, United States. 11. Boston University School of Medicine, Boston, MA, United States. 12. Boston Medical Center, Boston, MA, United States. 13. State University of New York Upstate Medical University, Syracuse, NY, United States. 14. New York University Grossman School of Medicine, NY, NY, United States. 15. Division of Cardiology, University of Washington, United States. 16. Mayo Clinic, Rochester, MN, United States. 17. Division of Rheumatology, University of Washington, Seattle, WA, United States. 18. Department of Epidemiology, University of Washington, United States.
Abstract
BACKGROUND: Treatment options for outpatients with COVID-19 could reduce morbidity and prevent SARS-CoV-2 transmission. METHODS: In this randomized, double-blind, three-arm (1:1:1) placebo-equivalent controlled trial conducted remotely throughout the United States, adult outpatients with laboratory-confirmed SARS-CoV-2 infection were recruited. Participants were randomly assigned to receive hydroxychloroquine (HCQ) (400 mg BID x1day, followed by 200 mg BID x9days) with or without azithromycin (AZ) (500 mg, then 250 mg daily x4days) or placebo-equivalent (ascorbic acid (HCQ) and folic acid (AZ)), stratified by risk for progression to severe COVID-19 (high-risk vs. low-risk). Self-collected nasal swabs for SARS-CoV-2 PCR, FLUPro symptom surveys, EKGs and vital signs were collected daily. Primary endpoints were: (a) 14-day progression to lower respiratory tract infection (LRTI), 28-day COVID-19 related hospitalization, or death; (b) 14-day time to viral clearance; secondary endpoints included time to symptom resolution (ClinicalTrials.gov: NCT04354428). Due to the low rate of clinical outcomes, the study was terminated for operational futility. FINDINGS: Between 15th April and 27th July 2020, 231 participants were enrolled and 219 initiated medication a median of 5.9 days after symptom onset. Among 129 high-risk participants, incident LRTI occurred in six (4.7%) participants (two control, four HCQ/AZ) and COVID-19 related hospitalization in seven (5.4%) (four control, one HCQ, two HCQ/AZ); no LRTI and two (2%) hospitalizations occurred in the 102 low-risk participants (one HCQ, one HCQ/AZ). There were no deaths. Among 152 participants with viral shedding at enrollment, median time to clearance was 5 days (95% CI=4-6) in HCQ, 6 days (95% CI=4-8) in HCQ/AZ, and 8 days (95% CI=6-10) in control. Viral clearance was faster in HCQ (HR=1.62, 95% CI=1.01-2.60, p = 0.047) but not HCQ/AZ (HR=1.25, p = 0.39) compared to control. Among 197 participants who met the COVID-19 definition at enrollment, time to symptom resolution did not differ by group (HCQ: HR=1.02, 95% CI-0.63-1.64, p = 0.95, HCQ/AZ: HR=0.91, 95% CI=0.57-1.45, p = 0.70). INTERPRETATION: Neither HCQ nor HCQ/AZ shortened the clinical course of outpatients with COVID-19, and HCQ, but not HCQ/AZ, had only a modest effect on SARS-CoV-2 viral shedding. HCQ and HCQ/AZ are not effective therapies for outpatient treatment of SARV-CoV-2 infection. FUNDING: The COVID-19 Early Treatment Study was funded by the Bill & Melinda Gates Foundation (INV-017062) through the COVID-19 Therapeutics Accelerator. University of Washington Institute of Translational Health Science (ITHS) grant support (UL1 TR002319), KL2 TR002317, and TL1 TR002318 from NCATS/NIH funded REDCap. The content is solely the responsibility of the authors and does not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. PAN and MJA were supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program.Trial registration ClinicalTrials.gov number NCT04354428.
BACKGROUND: Treatment options for outpatients with COVID-19 could reduce morbidity and prevent SARS-CoV-2 transmission. METHODS: In this randomized, double-blind, three-arm (1:1:1) placebo-equivalent controlled trial conducted remotely throughout the United States, adult outpatients with laboratory-confirmed SARS-CoV-2 infection were recruited. Participants were randomly assigned to receive hydroxychloroquine (HCQ) (400 mg BID x1day, followed by 200 mg BID x9days) with or without azithromycin (AZ) (500 mg, then 250 mg daily x4days) or placebo-equivalent (ascorbic acid (HCQ) and folic acid (AZ)), stratified by risk for progression to severe COVID-19 (high-risk vs. low-risk). Self-collected nasal swabs for SARS-CoV-2 PCR, FLUPro symptom surveys, EKGs and vital signs were collected daily. Primary endpoints were: (a) 14-day progression to lower respiratory tract infection (LRTI), 28-day COVID-19 related hospitalization, or death; (b) 14-day time to viral clearance; secondary endpoints included time to symptom resolution (ClinicalTrials.gov: NCT04354428). Due to the low rate of clinical outcomes, the study was terminated for operational futility. FINDINGS: Between 15th April and 27th July 2020, 231 participants were enrolled and 219 initiated medication a median of 5.9 days after symptom onset. Among 129 high-risk participants, incident LRTI occurred in six (4.7%) participants (two control, four HCQ/AZ) and COVID-19 related hospitalization in seven (5.4%) (four control, one HCQ, two HCQ/AZ); no LRTI and two (2%) hospitalizations occurred in the 102 low-risk participants (one HCQ, one HCQ/AZ). There were no deaths. Among 152 participants with viral shedding at enrollment, median time to clearance was 5 days (95% CI=4-6) in HCQ, 6 days (95% CI=4-8) in HCQ/AZ, and 8 days (95% CI=6-10) in control. Viral clearance was faster in HCQ (HR=1.62, 95% CI=1.01-2.60, p = 0.047) but not HCQ/AZ (HR=1.25, p = 0.39) compared to control. Among 197 participants who met the COVID-19 definition at enrollment, time to symptom resolution did not differ by group (HCQ: HR=1.02, 95% CI-0.63-1.64, p = 0.95, HCQ/AZ: HR=0.91, 95% CI=0.57-1.45, p = 0.70). INTERPRETATION: Neither HCQ nor HCQ/AZ shortened the clinical course of outpatients with COVID-19, and HCQ, but not HCQ/AZ, had only a modest effect on SARS-CoV-2 viral shedding. HCQ and HCQ/AZ are not effective therapies for outpatient treatment of SARV-CoV-2 infection. FUNDING: The COVID-19 Early Treatment Study was funded by the Bill & Melinda Gates Foundation (INV-017062) through the COVID-19 Therapeutics Accelerator. University of Washington Institute of Translational Health Science (ITHS) grant support (UL1 TR002319), KL2 TR002317, and TL1 TR002318 from NCATS/NIH funded REDCap. The content is solely the responsibility of the authors and does not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. PAN and MJA were supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program.Trial registration ClinicalTrials.gov number NCT04354428.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Ehud Chorin; Matthew Dai; Eric Shulman; Lalit Wadhwani; Roi Bar-Cohen; Chirag Barbhaiya; Anthony Aizer; Douglas Holmes; Scott Bernstein; Michael Spinelli; David S Park; Larry A Chinitz; Lior Jankelson Journal: Nat Med Date: 2020-06 Impact factor: 53.440
Authors: John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane Journal: N Engl J Med Date: 2020-10-08 Impact factor: 91.245
Authors: Ali S Omrani; Sameer A Pathan; Sarah A Thomas; Tim R E Harris; Peter V Coyle; Caroline E Thomas; Isma Qureshi; Zain A Bhutta; Naema Al Mawlawi; Reham Al Kahlout; Ashraf Elmalik; Aftab M Azad; Joanne Daghfal; Mulham Mustafa; Andrew Jeremijenko; Hussam Al Soub; Mohammed Abu Khattab; Muna Al Maslamani; Stephen H Thomas Journal: EClinicalMedicine Date: 2020-11-20
Authors: Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult Journal: Int J Antimicrob Agents Date: 2020-03-20 Impact factor: 5.283
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Adrian V Hernandez; John Ingemi; Michael Sherman; Vinay Pasupuleti; Joshuan J Barboza; Alejandro Piscoya; Yuani M Roman; C Michael White Journal: Arch Med Sci Date: 2021-10-24 Impact factor: 3.707
Authors: Jacob J Mayfield; Neal A Chatterjee; Peter A Noseworthy; Jeanne E Poole; Michael J Ackerman; Jenell Stewart; Patricia J Kissinger; John Dwyer; Sybil Hosek; Temitope Oyedele; Michael K Paasche-Orlow; Kristopher Paolino; Paul A Friedman; Chloe Waters; Jessica Moreno; Hannah Leingang; Kate B Heller; Susan A Morrison; Meighan L Krows; Ruanne V Barnabas; Jared Baeten; Christine Johnston; Arun R Sridhar Journal: Commun Med (Lond) Date: 2021-12-20
Authors: Matteo Bassetti; Daniele Roberto Giacobbe; Paolo Bruzzi; Emanuela Barisione; Stefano Centanni; Nadia Castaldo; Silvia Corcione; Francesco Giuseppe De Rosa; Fabiano Di Marco; Andrea Gori; Andrea Gramegna; Guido Granata; Angelo Gratarola; Alberto Enrico Maraolo; Malgorzata Mikulska; Andrea Lombardi; Federico Pea; Nicola Petrosillo; Dejan Radovanovic; Pierachille Santus; Alessio Signori; Emanuela Sozio; Elena Tagliabue; Carlo Tascini; Carlo Vancheri; Antonio Vena; Pierluigi Viale; Francesco Blasi Journal: Infect Dis Ther Date: 2021-07-30
Authors: H S C Paula; S B Santiago; L A Araújo; C F Pedroso; T A Marinho; I A J Gonçalves; T A P Santos; R S Pinheiro; G A Oliveira; K A Batista Journal: Braz J Med Biol Res Date: 2021-12-10 Impact factor: 2.590
Authors: Jenell Stewart; Meighan L Krows; Torin T Schaafsma; Kate B Heller; Elizabeth R Brown; Jim Boonyaratanakornkit; Clare E Brown; Hannah Leingang; Caroline Liou; Anna Bershteyn; Mark D Schwartz; Vaidehi Agrawal; DeAnna Friedman-Klabanoff; Stephen Eustace; Helen C Stankiewicz Karita; Michael K Paasche-Orlow; Patricia Kissinger; Sybil G Hosek; Helen Y Chu; Connie Celum; Jared M Baeten; Anna Wald; Christine Johnston; Ruanne V Barnabas Journal: JAMA Netw Open Date: 2022-02-01